Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 73Colonic Neoplasms 14Rectal Neoplasms 13Neoplasm Metastasis 12Stomach Neoplasms 8Pancreatic Neoplasms 5Advanced Solid Tumors 5Neoplasms 4Colorectal Cancer Metastatic 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Gallbladder Neoplasms 3Cholangiocarcinoma 3Carcinoma 3Adenocarcinoma 3Neutropenia 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Biliary Tract Neoplasms 2Bile Duct Neoplasms 2Advanced Solid Tumors (Excluding Breast Cancer) 2Advanced Colorectal Cancer 2Adenocarcinoma Of Esophagus 2mCRC 1Urologic Diseases 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Spinocerebellar Degenerations 1Solid Tumor Cancer 1Solid Tumor 1

Interventions

pembrolizumab 189Cisplatin 47Paclitaxel 45Carboplatin 44lenvatinib 31Docetaxel 23Pemetrexed 21Fluorouracil 20Capecitabine 17Gemcitabine 15Oxaliplatin 14Saline Solution 13Albumin-Bound Paclitaxel 11130-nm albumin-bound paclitaxel 10epacadostat 9Leucovorin 9Cetuximab 9olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6enzalutamide 5durvalumab 5belzutifan 5Nivolumab 5Dexamethasone 5Surgical Procedures, Operative 4Radiotherapy 4trifluridine tipiracil drug combination 3spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × trifluridine tipiracil drug combination × Clear all
NCT05064059 2026-05-26

MK-4280A-007

Merck Sharp & Dohme LLC

Phase 3 Completed
441 enrolled 24 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04776148 2026-02-05

MK-7902-017

Merck Sharp & Dohme LLC

Phase 3 Completed
563 enrolled 32 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05600309 2025-11-26

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Merck Sharp & Dohme LLC

Phase 3 Completed
94 enrolled 15 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡